Damora Therapeutics (DMRA) Net Cash Flow Growth (3y) (2022 - 2026)
Damora Therapeutics (DMRA) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 32.17% |
| 10 | Damora Therapeutics | 1.02 Bn | 820.75 Mn | - | 234.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 234.97% |
| Dec 31, 2025 | -41.17% |
| Sep 30, 2025 | -33.17% |
| Jun 30, 2025 | 46.84% |
| Mar 31, 2025 | 47.65% |
| Dec 31, 2024 | -12.77% |
| Sep 30, 2024 | -20.55% |
| Jun 30, 2024 | 32.27% |
| Mar 31, 2024 | 85.88% |
| Dec 31, 2023 | -26.50% |
| Sep 30, 2023 | -92.62% |
| Jun 30, 2023 | 33.54% |
| Mar 31, 2023 | -30.92% |
| Dec 31, 2022 | 36.82% |